Breaks Categories: News

ThursdayAug 03, 2017 12:00 pm

HempNewsBreaks – Micronet Enertec Technologies, Inc. (NASDAQ: MICT) Receives Largest Purchase Order Since 2012; Shares Higher

Micronet Enertec Technologies (NASDAQ: MICT) shares surged 34% this morning after the company said its Mobile Resource Management (MRM) subsidiary Micronet Ltd., via its wholly owned subsidiary Micronet Inc., has received purchase orders valued at approximately $4.3 million for its recently released TREQr5 product. The orders for the ruggedized telematics Android on-board computer were received by a fleet management solutions provider that is a current customer. The purchase order marks the largest order received for the company since 2012 and brings the company’s backlog to a record amount of $13.5 million. "The magnitude of these orders, and the fact that…

Continue Reading

ThursdayAug 03, 2017 9:08 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Management Quoted in “HIGH TIMES” Article

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the publication of “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work” on August 1, 2017, by Javier Hasse on the website of “HIGH TIMES,” a publication that’s served as the preeminent source for cannabis information since 1974. In the article, both Ram Mukunda, CEO of IGC, and Dr. Chuanhai Cao, the company’s key advisor, were quoted with respect to the potential therapeutic effects of THC on Alzheimer’s disease, which is noted as America’s most expensive ailment.…

Continue Reading

WednesdayAug 02, 2017 3:23 pm

HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, including cannabinoids, was recently spotlighted in an article on Technical420.com. The publication highlighted, in detail, several of the company’s key developments and growth catalysts. “During the last few months, Lexaria has improved its fundamental story through the following developments: 1) The company applied for a new patent from the U.S., 2) Lexaria has advanced its agreements and launched new businesses, 3) Expands its Reach into Asia, 4) Focused on R&D with major organizations, and 5) The company’s cash position has…

Continue Reading

WednesdayAug 02, 2017 11:22 am

HempNewsBreaks – ReWalk Robotics (NASDAQ: RWLK) Shares Higher on Publication of Restore™ System Enhancing Walking Ability for Stroke Survivors

Shares of ReWalk Robotics (NASDAQ: RWLK) are up 15% this morning after the company’s Restore™ System was utilized in a study published in the Journal of Science Translational Medicine. The study found that use of a soft suit exoskeleton system enabled normal walking ability for ambulatory patients following a stroke. The prototype utilized in the study was created by the Wyss Institute and is now moving toward commercialization by ReWalk Robotics. "The ongoing research at the Wyss Institute on soft exosuits adds a new dimension to exoskeletons that can potentially meet the needs of individuals that have had a stroke,…

Continue Reading

WednesdayAug 02, 2017 11:18 am

HempNewsBreaks – Celsion Corporation (NASDAQ: CLSN) Trading Higher following Positive Translational Data from OVATION Study

Celsion (NASDAQ: CLSN) this morning reported “convincing evidence” of gene transfer and immune system activity from its OVATION Study combining the company’s GEN-1 gene-mediated immunotherapy with the standard of care for newly diagnosed patients with advanced ovarian cancer. “These translational research findings demonstrate that GEN-1 in ovarian cancer patients is biologically active and creates a shift in the tumor microenvironment in the peritoneal cavity in a dose-dependent manner and promotes a pro-immune T-cell population dynamic in the tumor microenvironment,” Dr. Khursheed Anwer, Celsion’s executive vice president and chief science officer, stated in the press release. “These distinct immunological changes in…

Continue Reading

WednesdayAug 02, 2017 10:22 am

HempNewsBreaks – Dow Clinches New Record, Surpassing 22,000 with Boost from Apple (NASDAQ: AAPL)

The Dow Jones Industrial Average this morning rocketed past the 22,000 mark, clipping a new milestone with a boost from Apple, Inc. (NASDAQ: AAPL). Shares of the tech giant are up 5.7% at a new 52-week high of $158.67 in morning trade. The Dow earlier this year crossed the 20,000 mark for the first time in its 120-year history and currently moves in a 52-week range of 17,883.56-22,036.10. For more on the Dow’s record performance, visit: http://nnw.fm/M1Skp More from HempNewsBreaks ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton EyeGate Pharmaceuticals, Inc. (NASDAQ:…

Continue Reading

WednesdayAug 02, 2017 9:04 am

HempNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Announces Close of $15 Million Investment from Cannabis Wheaton

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the completion of Cannabis Wheaton Income Corp.’s (TSX.V: CBW) previously detailed purchase of $15 million of ABcann common shares at an agreed upon valuation of $2.25 per share. “We are pleased to have completed the initial funding phase of our partnership with Cannabis Wheaton and to welcome them as new equity holders in ABcann,” Aaron Keay, chief executive officer of ABcann, stated in the news release. “The initial investment represents Cannabis Wheaton's first funding allocation and we look forward to future investment from them, as both companies advance our respective…

Continue Reading

TuesdayAug 01, 2017 12:08 pm

HempNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Enrolls First Patient in Phase 2b Trial of EGP-437 for Cataract Surgery

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are down 8% in mid-day trade. The specialty pharmaceutical company this morning said it has enrolled the first patient in the phase 2b clinical trial to evaluate its EyeGate® II Delivery System and EGP-437 combination product for the treatment of pain and inflammation in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens). Top-line data is anticipated by year-end 2017. Under an exclusive worldwide licensing agreement signed with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier this year, a subsidiary of Valeant has commercial and manufacturing rights to…

Continue Reading

TuesdayAug 01, 2017 12:06 pm

HempNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Inks Binding LOI for Merger Transaction with CytoBioscience

Skyline Medical (NASDAQ: SKLN) shares are up 4% this morning on news that the company has signed a binding letter of intent for a merger transaction with CytoBioscience, a privately held biomedical company. CytoBioscience is a creator and manufacturer of devices used in human cell research and is focused on new therapeutic drug development. CytoBioscience also has relationships with hospitals and government entities that it aims to leverage to open new markets for Skyline Medical’s STREAMWAY® System operating room safety products. “This is a great opportunity for both companies. The CytoBioscience group has a deep pipeline of projects and contracts…

Continue Reading

TuesdayAug 01, 2017 9:02 am

HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for…

Continue Reading